Internal Medicine, Gastroenterology · San Clemente, CA
NPI
1174591994
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
655 Camino de Los Mares, 123
San Clemente, CA, 92673
Phone (949) 443-1546
Groups this clinician bills Medicare through
Medicare paid, 2024
$216K
3,489 services
Medicare patients, 2024
656
Average age 74
Drug cost, 2024
$561K
1,754 prescriptions
Company payments, 2025
$878
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Navjyot Gujral was code 88305 (surgical pathology examination), 1,807 times for 358 patients. In total Navjyot Gujral billed 3,489 services in 13 codes, and Medicare paid $216K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 88305 Surgical Pathology Examination | Office | 1,807 | 358 | $30.10 | $54K |
| 99214 Office E&M - Established | Office | 558 | 375 | $91.51 | $51K |
| 99204 Office E&M - New | Office | 330 | 330 | $116.37 | $38K |
| 45380 Lower GI Endoscopy - Other | Facility | 255 | 255 | $63.91 | $16K |
| 43239 Upper GI Endoscopy | Facility | 223 | 217 | $54.57 | $12K |
| 45385 Colonoscopy - Lesion Removal | Facility | 177 | 176 | $174.49 | $31K |
| 45378 Lower GI Endoscopy - Other | Facility | 58 | 58 | $110.49 | $6,408 |
| 43249 Upper GI Endoscopy | Facility | 34 | 33 | $83.14 | $2,827 |
| 99213 Office E&M - Established | Office | 19 | 17 | $70.88 | $1,347 |
| 45381 Lower GI Endoscopy - Other | Facility | 14 | 14 | $11.67 | $163 |
By year: 2022 $170K for 2,304 services; 2023 $222K for 3,129 services; 2024 $216K for 3,489 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88305 Surgical Pathology Examination | 1,807 | 358 | $30.10 | $54K |
Medicare prescription drug claims, 2024
In 2024, the drug Navjyot Gujral prescribed most often to Medicare patients was Pantoprazole Sodium, with 668 prescriptions and refills. In total Navjyot Gujral wrote 1,754 Medicare prescriptions that cost $561K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pantoprazole Sodium Generic | 668 | 1,829 | 268 | $8,367 |
| Famotidine Generic | 190 | 535 | 69 | $2,628 |
| Plenvu Peg3350/Sod Sul/Nacl/Kcl/Asb/C | 160 | 160 | 160 | $23K |
| Omeprazole Generic | 86 | 250 | 30 | $945 |
| Linzess Linaclotide | 62 | 146 | 30 | $76K |
| Rabeprazole Sodium Generic | 61 | 146 | 32 | $2,896 |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 53 | 53 | 52 | $3,332 |
| Sucralfate Generic | 46 | 48 | 24 | $4,705 |
| Colestipol Hcl Generic | 36 | 46 | Under 11 | $1,642 |
| Cholestyramine Cholestyramine (With Sugar) | 34 | 40 | 14 | $1,536 |
| Dexlansoprazole Dr Dexlansoprazole | 25 | 51 | Under 11 | $11K |
| Voquezna Vonoprazan Fumarate | 22 | 37 | Under 11 | $23K |
| Lactulose Generic | 21 | 28 | 12 | $294 |
| Creon Lipase/Protease/Amylase | 21 | 26 | Under 11 | $67K |
| Hydrocortisone Generic | 19 | 21 | 16 | $402 |
Brand drugs: 401 claims; generic drugs: 1,353 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Navjyot Gujral $878 ($878 in general payments such as food, travel and fees) from 9 companies. The largest payer was QOL Medical, LLC with $178.
| Company | Payments | Amount |
|---|---|---|
| QOL Medical, LLC | 8 | $178 |
| Ardelyx, Inc. ARDX | 6 | $172 |
| Janssen Biotech, Inc. JNJ | 1 | $144 |
| Phathom Pharmaceuticals, Inc. PHAT | 5 | $117 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 4 | $77.18 |
| Genzyme Corporation SNY | 2 | $68.95 |
| Regeneron Healthcare Solutions, Inc. REGN | 3 | $60.62 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $37.2 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.